News

Everyone's portfolio should include a couple of monster stocks. What do I mean by "monster"? I'm talking about companies that have a solid earnings track record and offer bright prospects down the

Most Biogen (NASDAQ: BIIB) shareholders are probably excited about the company's newly approved Alzheimer's drug Leqembi right about now, and it's no surprise why. Some commentators are calling for

Wayne Gretzky probably had no idea how much one thing he said would be repeated through the years. But one of his most famous statements certainly was memorable and worthy of repetition: "I skate to

You don't have to settle for puny dividend income. Thousands of stocks offer dividends. Many of them, though, have dividend yields that don't amount to a hill of beans.

What if you could invest in

If you are looking for a high-yield dividend stock to boost your income, you might be interested in Altria (NYSE: MO) or Viatris (NASDAQ: VTRS). Both companies offer attractive dividend yields of

Shares of telecom giant AT&T (NYSE: T) are historically inexpensive. Based on the company's guidance for 2023, the stock trades at a measly 7 times free cash flow. The dividend yield is also on the

Shares of telecom giant AT&T (NYSE: T) fell 3.6% as of 9:50 a.m. ET Friday morning.

You can blame J.P. Morgan for that.

This morning, investment bank J.P. Morgan downgraded AT&T stock from

Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof

When looking for stocks that can make one richer, investors often start with names they know. The problem is that the names they know also tend to be the names that everyone knows, and these stocks

Vertex Pharmaceuticals (NASDAQ: VRTX) has climbed nearly 20% so far this year. And that leaves the stock trading a few dollars off its record high. It's not surprising Vertex has advanced. The

Shares of Novavax (NASDAQ: NVAX) lost 28% of their value in the first six months of the year, according to data from S&P Global Market Intelligence, extending a downtrend that began in early 2022

Amgen (NASDAQ: AMGN) is a global leader in biotechnology, with a market capitalization of over $121 billion. The company has a proven track record of developing breakthrough therapies for

Investing $100 can be a good amount to get started in stocks, especially if you're using a brokerage that charges low commission fees or none at all. And over time, you can steadily grow your

Healthcare stocks, particularly pharmaceutical stocks with solid dividends, make great long-term investments.

In general, the need for healthcare products and services is stable, even during

In the financial coliseum of 2023, we find AT&T (NYSE: T) and its investors locked in a high-stakes bull-versus-bear duel. The telecom giant, a perennial darling for dividend-seekers, has found

Investors in Biogen (NASDAQ: BIIB) got some great news last week as the Food and Drug Administration (FDA) approved the company's Alzheimer's drug Leqembi. But despite the big win, the stock didn't

Make money. That's every investor's goal. How each person chooses to achieve that goal makes the difference in exactly how much money they make and how long it takes to make it.

Some stocks are

Shares of Silk Road Medical (NASDAQ: SILK) were down more than 33% as of 12:30 p.m. on Wednesday after the Centers for Medicare & Medicaid Services (CMS) announced a proposed change that could

The S&P 500 is up 15% this year, and there are many stocks that have been performing much better than that. Shares of Hims & Hers Health (NYSE: HIMS) and Viking Therapeutics (NASDAQ: VKTX) have been

High dividend yields are attractive to investors. Who doesn't want a large stream of steady income? However, there's more to it than that, as there is an underlying asset to the dividend that could